XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy

Journal of Clinical Oncology

Volumn 22, Issue 13, 2004, Pages 2594-2601

  Gurubhagavatula, Sarada ^a   Liu, Geoffrey ^a   Park, Sohee ^a   Zhou, Wei ^a   Su, Li ^a   Wain, John C ^a   Lynch, Thomas J ^a   Neuberg, Donna S ^a   Christiani, David C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM; CISPLATIN; DNA BINDING PROTEIN; ERCC2 PROTEIN, HUMAN; HELICASE; PROTEIN; TRANSCRIPTION FACTOR; X RAY REPAIR CROSS COMPLEMENTING PROTEIN 1; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DNA CROSS LINKING; DNA REPAIR; FEMALE; GENE; GENE ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; XPD GENE; XRCC1 GENE; CLINICAL TRIAL; DNA DAMAGE; GENETICS; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DNA DAMAGE; DNA HELICASES; DNA REPAIR; DNA-BINDING PROTEINS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROGNOSIS; PROSPECTIVE STUDIES; PROTEINS; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 4344567395     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.067     Document Type: Article

References (41)

1. Travis WD, Lubin J, Ries L, et al: United States lung carcinoma incidence trends: Declining for most histologic types among males, increasing among females. Cancer 77:2464-2470, 1996
2. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54:594-606, 1993
3. Pisani P, Parkin DM, Ferlay J: Estimates of the worldwide mortality from eighteen major cancers in 1985: Implications for prevention and projections of future burden. Int J Cancer 55:891-903, 1993
4. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2002. CA Cancer J Clin 52:23-47, 2002
5. Salgia R, Skarin AT: Molecular abnormalities in lung cancer. J Clin Oncol 16:1207-1217, 1998
6. Greatens TM, Niehans GA, Rubins JB, et al: Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med 157:1093-1097, 1998
7. Wei Q, Cheng L, Amos CI, et al: Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: A molecular epidemiologic study. J Natl Cancer Inst 92:1764-1772, 2000
8. Cheng L, Spitz MR, Hong WK, et al: Reduced expression levels of nucleotide excision repair genes in lung cancer: A case-control analysis. Carcinogenesis 21:1527-1530, 2000
9. Wei Q, Cheng L, Hong WK, et al: Reduced DNA repair capacity in lung cancer patients. Cancer Res 56:4103-4107, 1996
10. Rosell R, Lord RV, Taron M, et al: DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38:217-227, 2002
11. Friedberg EC: How nucleotide excision repair protects against cancer. Nat Rev Cancer 1:22-33, 2001
12. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised trials. BMJ 311:899-909, 1995
13. Bunn PA, Kelly K: New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 4:1087-1100, 1998
14. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633-641, 1988
15. Stephens RJ, Fairlamb D, Gower N, et al: The Big Lung Trial (BLT): Determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC)-Preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 21:2002 (abstr 1161)
16. Giaccone G: Clinical perspectives on platinum resistance. Drugs 59:9-17, 2000 (suppl 4)
17. Bosken CH, Wei Q, Amos CI, et al: An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 94:1091-1099, 2002
18. Johnson SW, Stevenson JP, O'Dwyer PJ: Cisplatin and its analogues, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 6). Philadelphia, PA, Lippincott Williams and Wilkins, 2001, pp 376-388
19. Jordan P, Carmo-Fonseca M: Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57:1229-1235, 2000
20. Reed E, Ozols RF, Tarone R, et al: Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A 84:5024-5028, 1987
21. van de Vaart PJ, Belderbos J, de Jong D, et al: DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 89:160-166, 2000
22. Furuta T, Ueda T, Aune G, et al: Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62:4899-4902, 2002
23. Reed E: Cisplatin and analogs, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice (ed 3). New York, NY, Lippincott Williams and Wilkins, 2001, pp 447-465
24. Shellard SA, Fichtinger-Schepman AM, Lazo JS, et al: Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 4:491-500, 1993
25. Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24:331-344, 1998
26. de Boer J, Hoeijmakers JH: Nucleotide excision repair and human syndromes. Carcinogenesis 21:453-460, 2000
27. Lunn RM, Helzlsouer KJ, Parshad R, et al: XPD polymorphisms: Effects on DNA repair capacity. Carcinogenesis 21:551-555, 2000
28. Hoeijmakers JH, Egly JM, Vermeiden W: TFIIH: A key component in multiple DNA transactions. Curr Opin Genet Dev 6:26-33, 1996
29. Sung P, Bailly V, Weber C, et al: Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature 365:852-855, 1993
30. Butkiewicz D, Rusin M, Enewold L, et al: Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 22:593-597, 2001
31. Spitz MR, Wu X, Wang Y, et al: Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61:1354-1357, 2001
32. Duell EJ, Wiencke JK, Cheng TJ, et al: Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21:965-971, 2000
33. Wei Q, Frazier M, Levin B: DNA repair: A double-edged sword. J Natl Cancer Inst 92:440-441, 2000
34. Diasio RB: Pharmacogenetics, in Chabner B, Longo D (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice (ed 3). New York, NY, Lippincott Williams and Wilkins, 2001, pp 998-1011
35. Iyer L, Ratain MJ: Pharmacogenetics and cancer chemotherapy. Eur J Cancer 34:1493-1499, 1998
36. McLeod H, Papageorgio C, Watters JW: Using genetic variations to optimize cancer chemotherapy. Clin Adv Hematol Oncol 1:107-111, 2003
37. Sarries C, Haura EB, Roig B, et al: Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics 3:763-780, 2002
38. Park DJ, Zhang W, Stoehlmacher J, et al: ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 1:162-166, 2003
39. Park DJ, Stoehlmacher J, Zhang W, et al: A xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61:8654-8658, 2001
40. Camps C, Sarries C, Roig B, et al: Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin- treated advanced non-small-cell lung cancer patients. Clin Lung Cancer 4:237-241, 2003
41. Resell R, Taron M, Alberola V, et al: Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 41:S97-S102, 2003 (suppl 1)